Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 29Breast Neoplasms 10Neoplasms 2Stage II Prostate Adenocarcinoma 1Salivary Gland Neoplasms 1Prostatectomy 1Prostate Cancer Metastatic Disease 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Metastatic Castration-resistant Prostate Cancer 1Highly Endocrine Responsive Operable Breast Cancer 1Cardiovascular Diseases 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

enzalutamide 3testosterone 17 beta-cypionate 2darolutamide 2abiraterone 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1pamiparib 1olaparib 1lactitol 1fluciclovine F-18 1enfortumab vedotin 1cabazitaxel 1avelumab 1Standard of Care 1Selegiline 1Prednisolone 1Pluvicto 1PSMA-617 1Gonadotropin-Releasing Hormone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-resistant Prostate Cancer × Gonadotropin-Releasing Hormone × Clear all
NCT07476001 2026-05-15

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
12 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡